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18 Sexually transmitted diseases (STDs) 
Donald E. Greydanus, jane Seyler, and Hatim A. Omar 
High rates of unprotected sexual behavior in adolescents result in millions of cases of 
STDs in the world. This chapter reviews factors inducing high STD rates, specific STDs, 
and their management based on 2010 U.S. Centers for Disease Control and Prevention 
(CDC) STD guidelines. Clinicians should screen all their sexually active adolescent 
pati ents for STDs and provide preventive education as well as treatment measures. 
18.1 Introduction 
There are many STDs, which can infect adolescents (see ~Tab. 18.1) (1,2,3,4,5). Sex-
ually active adolescents are at risk for STDs due to their high rates of sexual activity, 
multiple sex partners, immature cervix (cervical ectropion, which is a good media 
for growth of some STD agents), other high risk behaviors that encourage sexual behav-
ior (i.e. substance abuse, body piercing, tattoos), mistrust of adults in general , problems 
travers ing the medical system, and an often pervasive belief ("magical thinking") that 
they are not susceptible to acquiring STDs. The growth of social networks in the past 
20 years has led to another risk factor for allowing youth to meet and acquire STDs. 
Adolescents receive limited sexual education in the United States, have accidental or 
irregular sexual relationships, change sexual partners ("serial monogamy"), and fail 
to use condoms on a regular basis. 
The result is that 19 million STDs are acquired in the United States each year, 
mainly in the 14- to 29-year-old age group; one in six sexually active adolescents 
(15 to 19 years of age) acquire an STD each year, and one in three persons acquire 
an STD by age 24 years. Those at the highest risk for an STD include runaway 
youth, those involved in survival sex (prostitution), those in jails or detention centers, 
those involved in male homosexual activity, and youth with a history of STDs. The 
most common STDs among youth are infections due to HPV (6,7,8,9), HSV 
(1 0,11 ), C. trachomatis (12,13), N. gonorrhoeae (14), and T. vagina/is (15,16,17,18,1 9). 
The highest rates of chlamydia! and gonococcal infections are in 15- to 19-year-old 
females, while HPV acquisition is often during adolescence. Oral sexual behavior is 
noted in one-third to one-half of youth and can lead to the acquisition of various 
STDs including HPV, HSV, syphilis, gonorrhea, and others. Cl inicians should note 
that N. gonorrhoeae is part of the differential diagnosis of pharyngitis in adolescents 
(see ~Tab. 18.2), and thus quest ions about oral sexual behavior are important even 
when sore throat is the only presentation. 
Primary prevention of STDs involves proper counseling of youth regarding STDs (in-
cluding HIV), use of latex condoms for all sexually active youth, and immunization 
with HPV, hepatitis A, as well as hepatitis B vaccines (including for males having 
sex with men and illicit drug users). Use of a condom is a marker for improved 
risk behavior in adolescents and is beneficial in lowering STD rates, especially with 
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Tab. 18.1: STD agents (diseases or infections; STDs or sexually transmitted infections [STis]). 
Human papillomavirus (HPV) 
Trichomonas vagina/is 
Chlamydia trachomatis 
Neisseria gonorrhoeae 
Herpes simplex virus (HSV) 
Hepatitis A, B, C 
Haemophilus ducreyi (chancroid) 
Pediculosis pubis 
Sarcoptes scabiei (scabies) 
Cardnerel/a vagina/is (bacterial vaginosis, or BV) 
(sexually associated) 
Human immunodeficiency virus (HIV) Klebsiella granulomatis (lymphogranuloma venereum, 
or LGV) 
Treponema pallidum (syphilis) 
Molloscum contagiosum 
Oonovania granulomatis (Granuloma 
inguinale) 
Behcet' s disease 
Reiter's syndrome 
Others 
Tab. 18.2: Differential diagnosis of exudative, diffuse, or membranous pharyngitis. 
Cause 
Group A P- hemolytic 
streptococcus 
Infectious mononucleosis 
(Epstein-Barr virus) 
Gonococcal pharyngitis 
(N. gonorrhoeae) 
Description 
Exudative, diffuse, or 
membranous type. Other 
features: strawberry tongue, 
tender anterior cervical 
lymphadenopathy, fever, 
leukocytosis, dysphagia, and 
headache. Minimal coryza and 
cough. Positive throat culture. 
Scarlet fever can occur. Can 
occur with infectious 
mononucleosis. 
Exudative, diffuse, or 
membranous erythema. 
Periodic fever, 
lymphadenopathy (especially 
anterior cervical), 
splenomegaly, absolute 
lymphocytosis, positive 
heterophil agglutination test (or 
other serologic evidence of 
infectious mononucleosis) . 
Exudative pharyngitis or diffuse 
erythema of the oropharynx 
associated with anterior 
cervical lymphadenopathy and 
history of oral sex with an 
Treatment 
1.2 million U benzathine 
penicillin intramuscularly 
(IM) or oral penicillin, 250 
mg, qid x 1 0 days; 
erythromycin, 250 mg, qid x 
10 days; 
Cefaclor: 250 mg qid x 1 0 
days; others. 
Supportive 
Ceftriaxone 250 mg IM + 
treatment for C. trachomatis: 
see box "Treatment of C. 
trachomatis Cervicitis 
(Urethritis)" 
(Continued) 
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Tab. 18.2: Differential diagnosis of exudative, diffuse, or membranous pharyngitis. (Continued) 
Cause 
Adenovirus pharyngitis 
Acute lymphonodular 
pharyngitis 
(coxsackievirus Awl 
Herpangina 
(coxsackievirus A) 
Hand, foot, and mouth 
disease (coxsackievirus A16) 
Postanginal sepsis 
(Fusobacterium 
necrophorum and 
Bacteroides species) 
Corynebacterium 
haemolyticum 
qid, four times daily. 
Description 
infected sexual partner. Often 
asymptomatic. Pharynx may 
be the only site of infection 
in 1%-4% of teenagers with 
gonorrhea. 
Common cause of 
nonstreptococcal exudative 
pharyngitis and nasopharyngitis 
and foil icu lar pharyngitis; 
diffuse erythema also noted, 
with fever, coryza, and cough. 
Raised, white or yellow les ions 
with surrounding erythema on 
the posterior pharynx. 
Papulovesicular lesions leading 
to ulcerations occur on the 
pharynx. Presents as a febrile 
illness- often in the summer. 
Echovirus and enterovirus also 
implicated. 
Vesicular and ulcerative lesions 
in the mouth and pharynx with 
vesicular eruptions over hands 
and feet. 
Evidence of pharyngeal 
infection followed by high 
fever, chills, anterior cervicitis, 
multiple abscesses, jaundice, 
etc. 
Variable pharyngitis associated 
with a scarlatiniform eruption of 
arms and legs with eventual 
scaling of hands and feet in 
some. Urtica rial rash and 
erythema nodosum noted in 
some. 
Treatment 
Supportive 
Supportive 
Supportive 
Supportive 
Caused by anaerobic 
bacteria. Treatment involves 
antibiotics - depending on 
culture resu lts- penicillin, 
clindamycin, metronidazo le, 
etc. 
Erythromycin, 250 mg, qid x 
10 days. Penicillin not 
reliabl e. 
N. gonorrhoeae C. tra chomatis, and HIV. Spermicides with nonoxynol-9 are not re-
commended at this time because of their failure to prevent various STDs and potenti al 
injury to the surface of epithelial cells linked with its use that may enhance the 
acquisition of HIV. 
Secondary prevention of STDs involves regul ar STD screening of all sexually 
active youth, evaluation for STDs, proper treatment of identified STDs (including 
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asymptomatic infection), and partner notification in the presence of STDs. Screening ). 
sexually active teenagers and adults includes annual testing for C. trachomatis (up to 
age 25 years); annual testing for N. gonorrhoeae, if at risk; and annual HIV screening, 
if sexually active as well as using injection drugs. Self-collection vaginal swabs for 
C. trachomatis and N. gonorrhoeae are becoming increasingly acceptable to adoles-
cent females. One should consult with the CDC 2010 STD guidelines for STD manage-
ment including STDs in special circumstances, such as STDs in pregnancy, males 
having sex with men (MSM), STDs in children, women having sex with women, 
those in correctional institutions, and others. 
18.2 C. trachomatis 
Two species of Chlamydia are recognized: Chlamydia psittaci (causing psittacosis) and 
C. trachomatis. The latter consists of different subspecies, which can cause cervicitis, 
urethritis, trachoma, and/or lymphogranuloma venereum. C. trachomatis is an obligate 
intracellular microbe, which causes the most commonly reported bacterial STD in the 
United States and, as noted with STDs, is disproportionately increased in minority ado-
lescent females. It causes cell damage with a significant inflammatory host cell immune 
response. Two to three million infections are estimated to occur each year in the United 
States, and the prevalence in 18 to 26 year olds is nearly 5 percent in females and 
nearly 4 percent in males. 
C. trachomatis is a bacteria that can cause a variety of infections (see the following 
box) that include cervicitis, urethritis (with dysuria, urethral discharge [often thin]), 
epididymitis, proctitis, pharyngitis, proctitis, perihepatitis (Fitz-Hugh-Curtis syndrome), 
and endocervicitis (pelvic inflammatory disease, or PI D) (12,13). All sexually active fe-
males under age 25 years should be screened annually for the presence of this bacteria, 
which can be silent (asymptomatic) in half or more of those infected. A variety of diag-
nostic tests are available, as noted in )iJ> Tab. 18.3. Nucleic acid amplification testing 
(NAAT) and DNA probes can be done on vaginal or cervical material as well as 
urine. NAAT sensitivity is excellent, in the rage of 87 percent to 97 percent. 
Tab. 18.3: Diagnostic tests for C. trachomatis. 
Cell culture ("gold standard") 
Polymerase chain reaction (PCR) test (NAAT) 
Ligase chain reaction test (NAAT) 
Enzyme-linked immunoassay (EIA, ELISA) 
Direct fluorescent antibody (DFA) 
DNA probes (Gen-Probe; direct hybridization probe test) 
LET (leukocyte esterase dipstick) 
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18.3 Cervicitis 
This can present in various ways, though there typically is purulent or mucopurulent 
cervical discharge, erythema of the vaginal erythema, and hypertrophic cervical 
erosion . Mixed infections with other STDs are common, especially N. gonorrhoeae. 
Treatment of cervicitis due to C. trachomatis is outlined in the following box. When 
diagnosis cannot be confirmed, treatment for N. gonorrhoeae should be included due 
to the high incidence of coinfections. Azithromycin is effective for chlamydia! infections 
in pregnancy. 
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18.4 Urethritis and epididymitis 
Urethritis due to C. trachomatis is usually present with dysuria and a thin or nonpuru-
lent urethral discharge; mucopurulent or purulent discharge may also be seen. It may 
be present with other STD agents including N. gonorrhoeaeUreaplasma urealyticum, 
or T. vagina/is. Urethritis due to C. trachomatis and U. urealyticum have the same clin-
ical appearance and both usually respond to doxycycline or erythromycin . Male 
urethritis may also be due to Mycoplasma genitalium or HSV. 
A first-void urine evaluation may reveal the presence of T. vagina/is in those with 
nongonococcal urethritis (NGU). Dysuria associated with pyuria can be due to C. tra-
chomatis (urethral syndrome). Pharyngitis is uncommon and usually due to N. gonor-
rhoeae or HSV. Caucasian males with HLA-B27 who develop chlamydia! urogenital 
infection may subsequently develop Reiter's syndrome. PID, ectopic pregnancy, and 
infertility may occur. 
The recommended treatment schedule for uncomplicated chlamydia urethritis is 
azithromycin (1 gram orally in a single dose) or doxycycline (1 00 mg twice a day orally 
for 7 days) (see the previous box, "Treatment of C. trachomatis Cervicitis"). Azithromy-
cin is preferred for those who may be nonadherent due to its single dosing regimen, 
while erythromycin may lead to nonadherence due to gastrointestinal intolerance. 
Alternative treatments include erythromycin base (500 mg orally four times a day 
for 7 days), erythromycin ethylsuccinate (800 mg orally, four times a day for 
7 days), ofloxacin (300 mg orally twice a day for 7 days), or levofloxacin (500 mg orally 
for 7 days) . Doxycycline, ofloxacin, and levofloxacin are contraindicated in preg-
nancy. Recommended regimens for the pregnant patient include azithromycin 
(1 gram orally) or amoxicillin - 500 mg orally three times a day 7 days. Alternatives 
for the pregnant patient include erythromycin base (not estolate) - 500 mg four times 
a day orally for 7 days or 250 mg orally, four times a day for 14 days; also, erythromycin 
ethylsuccinate (400 mg, orally four times a day for 14 days or 800 mg four times a day for 
7 days) can be used. Erythromycin estolate is contraindicated in pregnancy due to 
drug-induced hepatotoxicity. Follow-up evaluation is necessary, as is treatment of 
sexual contacts. 
Treatment of recurrent and persistent urethritis with other regimens (if there was 
compliance with the regimens already noted and reexposure did not occur) includes 
metronidazole (2 grams orally in a single dose) or tinidazole (2 grams orally in a single 
dose) plus azithromycin (1 gram orally) if not used already. M. genitalium is best treated 
with azithromycin. Epididymitis due to C. trachomatis or N. gonorrhoeae is treated with 
ceftriaxone (250 mg IM in a single dose for the gonorrhea) plus doxycycline (1 00 mg 
orally twice daily [BID] for 10 days); alternative regimens, if the infection is due to 
enteric organisms, include ofloxacin (300 mg orally BID for 10 days) or levofloxacin 
(500 mg orally once daily for 10 days) (1 ). For males at risk for both types of pathogens, 
ceftriaxone plus a fluoroquinolone is recommended. 
18.5 N. gonorrhoeae 
There are an estimated 1 million cases of gonorrhea in the United States each year, and 
at least 25 percent of cases occur in the 10- to 19-year-old age group. N. gonorrhoeae 
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is a bacteria (gram-negative diplococcus) that can produce urethritis, cervicitis, epidid-
ymitis, proctitis, conjunctivitis (neonatal ophthalmia), pharyngitis, perihepatitis, endo-
cervicitis (PID), disseminated gonococcal infection (DGI with dermatitis and arthritis), 
and others (14). Classically, this organism produces a vaginitis in prepubertal girls 
and a cervicitis (with or without salpingitis) in pubescent girls and adult women. 
Gonorrhea has a tendency to infect the columnar epithelium of the cervical canal 
and the urethra, producing a carrier state that can last for months to years. This organ-
ism of antiquity possesses a genetic-based proclivity to alter antigenic structures on 
surfaces. 
After an incubation period of 2 to 6 days, the symptomatology is protean, but usually 
there is a yellowish-green, mucopurulent endocervical discharge associated with min-
imal pruritus and with possible tenderness noted on cervical motion; the dysuria can be 
severe. Purulent endocervical discharge is a hallmark of gonorrhea, but this can be 
noted with trichomoniasis, chlamydia! infection, and HSV infection. Abnormal uterine 
bleeding and urinary tract infection symptoms are also typical of gonorrhea. It can also 
cause a urethritis, dysuria/urethral discharge syndrome, salpingitis, proctitis, pharyngi-
tis, conjunctivitis, and DGI in females. In males, it may lead to urethritis, epididymitis, 
proctitis, pharyngitis, conjunctivitis or DGI. 
Urethritis is defined by classic symptoms (dysuria, urethral discharge) along with 
finding five or more polymorphonuclear leukocytes (PMNs)/1,000X magnification 
versus cervicitis with more than 30 PMNs/1,000X magnification. A Gram stain of 
the discharge reveals pairs of gram-negative, kidney-bean-shaped diplococci in the 
PMNs; this test is diagnostic in males but has decreased sensitivity in females. 
Other confirmatory laboratory testing includes culture on selective medium (Thayer-
Martin medium in a 10 percent carbon dioxide environment), urinary PCR (NAAT) 
testing, or DNA hybridization testing (i.e. Gen-Probe). Approximately 50 percent of 
NGU have no defined organism; identified etiologic agents include C. trachomatis 
M. genitalium, adenoviruses, HSV, and others (20). NGU typically has an incubation 
period of 2 to 3 weeks, an insidious onset, and intermittent dysuria as well as variable 
discharge. 
Management of uncomplicated gonococcal infections of the cervix, urethra, or rec-
tum is noted in ~Tab. 18.4. Screen adolescents with N. gonorrhoeae for C. trachoma-
tisT. pallidum, and HIV. Treatment should also include coverage for C. trachomatis 
since it is present in up to 40 percent of cases (~Tab. 18.3). Unfortunately, antibiotic 
resistance, a phenomenon begun in the twentieth century, is worsening in the 
twenty-first century; this includes resistance to penicillin, tetracycline, spectinomycin, 
quinolones, and floxacins. Other cause of male urethritis are noted above under C. tra-
chomatis. Treatment of uncomplicated gonococcal infection of the pharynx is with cef-
triazone (250 mg IM) plus azithromycin (1 gram orally) or doxycycline (1 00 mg twice a 
day for 7 days). 
18.6 PID 
PID is a polymicrobial infection of female genital tract that can include C. trachomatis 
and N. gonorrhoeae, this polymicrobial infection may involve such agents found in the 
vagi no-cervical endogenous flora- such as G. vagina/is, beta-hemolytic streptococcus, 
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Neisseria meningitides M. genitalium Bacteroides fragilis Streptococcus faecalis, 
U. urealyticum Haemophilus influenzae, coliforms (enterobacteriaceae), cytomegalo-
virus, peptostreptococcus, and other anaerobes (21 ,22). Screening for and management 
of C. trachomatis can help to prevent PI D . .,. Tab. 18.5 notes CDC criteria for PID that 
revolve around lower genital tract inflammation with pelvic organ tenderness. The 
following box, "Differential Diagnosis of PID," notes the differential diagnosis for 
PID; if PID is clinically severe, consider hospitalization and imaging to look for 
tuba-ovarian abscess. 
Tab. 18.4: Antibiotic management of gonococcal infections of the cervix, urethra, or rectum 
(uncomplicated) (1 ). 
1. Ceftriaxone, 250 mg IM, one dose, or (if not an option) 
2. Cefixime, 400 mg, orally, one dose, or 
3. Single-dose injectable cephalosporin regimens 
a. Ceftizoxime 500 mg IM 
b. Cefotaxime 500 mg IM 
c. Cefoxitin 2 grams IM + probenecid (1 gram orally) 
Plus 
Azithromycin (1 gram orally in one dose) or 
Doxycycline (1 00 mg orally twice a day, 7 days) 
Tab. 18.5: Diagnostic criteria for PID (1 ). 
1. Minimal criteria 
a. Uterine tenderness, or 
b. Adnexal tenderness, or 
c. Tenderness on cervical motion 
2. Additional criteria 
a. Cervical (vaginal) mucopurulent discharge 
b. Oral temperature over 101 degrees F (over 38.3 degrees C) 
c. Examination of saline drop from discharge: see white blood cells 
d. Elevated C-reactive protein 
e. Elevated erythrocyte sedimentation rate 
f. Positive lab test for C. trachomatis or N. gonorrhoeae infection 
3. Specific criteria 
a. Positive biopsy of endometrium showing endometritis 
b. Evidence of PID on laparoscopy 
c. Ultrasound (transvaginal) or MRI shows fallopian tubes that are thick and filled with fluid; 
may be free fluid in the pelvis or a tuba-ovarian complex. 
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~Tab. 18.6 notes CDC-recommended treatment options that seek to provide polymi-
crobial antibiotic coverage to conta in the infection (including facultative and anaerobic 
bacteri a) and prevent sequelae. In those with mild to moderate disease, oral and intra-
venous therapy are considered equally effective. For those receiving intravenous anti-
biotics, therapy may be stopped after 24 hours of clinical improvement with 
continuation of doxycycl ine for 14 days total. Intravenous (IV) doxycycline infusion 
can be very painful, and oral doxycycline may thus be preferred. Anaerobic coverage 
should be included in the presence of a tubo-ovarian abscess. 
Tab. 18.6: Antibiotic management of PID (1 ). 
Oral 
• Ceftrixone 250 mg IM in a single dose or cefoxitin 2 g IM in a single dose and probenecid 1 g 
orally concurrently or other third-generati on cephalosporin (as ceftizoxime or cefotaxime) 
Plus 
• Doxycycl ine 100 mg ora lly twice a day for 14 days with or without metronidazo le 500 mg ora lly 
twice a day for 14 days 
Parentera l 
• Regimen A 
Cefotetan 2 g IV every 12 hours or cefoxitin 2 g IV every 6 hours plus doxycycline 100 mg ora lly 
or IV every 12 hours 
• Regimen B 
Clindamycin 900 mg IV every 8 hours plus gentamicin loading dose IV or IM (2 mg/kg body 
weight) followed by a maintenance dose (1 .5 mg/kg) every 8 hours. Single daily dosing (3-5 mg/kg) 
can be substituted. · 
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18.7 Fitz-Hugh-Curtis syndrome 
The Fitz-Hugh-Curtis Syndrome (perihepatitis) is due to inflammation of the liver cap-
sule after genital infection with N. gonorrhoeae or C. trachomatis. There may or may 
not be symptomatic genital infection at the t ime the perihepatitis presents. Acute, 
severe, and knife-like right upper quadrant pain develops with or without right shoulder 
pain, right costal margin friction rub, and abdominal rebound or rigidity. Fever, nausea, 
emesis, hiccups, pleurisy, and pleuritic chest pain may also occur. The erythrocyte sed-
imentation rate (ESR) is elevated, and the liver function tests (LFT) are usually normal, 
though transient rise in LFTs has been reported. A laparoscopy will usually demonstrate 
the perihepatic inflammation and/or presence of the adhesions between the anterior 
abdominal wall and the liver. Most acute cases will have a positive cervical culture 
for gonorrhea or chlamydia. The liver enzymes (if elevated) are normalized quickly 
after antibiotic treatment. 
Differential diagnosis includes other sources of right upper quadrant pathology, in-
cluding cholecystitis, pancreatitis, peptic ulcer disease, hepatitis, pyelonephritis, pleu-
risy (with or without pneumonia), pulmonary embolism, pleurodynia, herpes zoster, 
and others. A rapid response to antibiotics is usually noted. Some individuals develop 
chronic pain due to the adhesions, requiring lysing of them for pain relief via laparo-
scopy. The correct diagnosis is based on a high index of suspi cion in a sexually active 
female with right upper quadrant and gonococcal or chlamydia! infection, which im-
proves with antibiotics or is confirmed via laparoscopy. Treat as per PID management 
guidelines (.,..Tab. 18.6) via the 2010 CDC STD treatment guidelines (1 ). 
18.8 DGI 
Approximately 3 percent of women and 1 percent of men with gonorrhea may develop 
septicemia leading to DGI, with evidence of dermatitis, arthritis or tenosynovitis, peri-
hepatitis, meningitis, endocarditis, and others; the most common form of DGI is the 
dermatitis-arthritis syndrome. The most common form of dermatitis is the vesicular pus-
tule (4 mm to 2.5 em) which is noted within 2-4 weeks of the urethral gonorrhea and is 
found as 2-9 lesions on the extensor surface of the hands, dorsal surface of the ankles 
and toes, and other areas. They appear in crops or at different times and probably rep-
resent gonococcal embolization or an immunologica lly mediated vasculitis. A positive 
Gram stain and/or cu lture of the les ions may be noted. The pustules develop into pig-
mented les ions and clear without scarring in 1-2 months. Sometimes purpuric macules 
on the palms or soles appear, as well as hemorrhagic bullae in various areas, or a pe-
techial rash over the hands, feet, and ankles. The oral mucosa and scalp are usually 
spared. Secondary lymphadenopathy does occur. 
A polyarthritis or monarthritis (tenosynovitis) has been described in the medical I it-
erature, but the pattern is variable. Many joints may be involved, including the knee, 
ankle, wrist, the small joints of the hands or feet, sternoclavicular joints, and others. 
The monarticular type often affects the knee. The joint fluid is frequently opaque or 
slight ly cloudy, has a poor mucin clot, increased protein and variable leukocytosis 
(1 0,000-1 00,000 per cu mm). Gonococcal dermatitis (see section 18.7) and elevated 
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ESR often occur. Tenosynovitis (dorsa of hands or feet, wrists, Achilles tendon, and 
others) also occurs. The ESR rate falls with effective therapy (as ceftriaxone 1 gram 
IV daily for 7-10 days). Joint destruction occurs without treatment. The urethral dis-
charge may be minimal or absent when DGI symptoms appear. Gonococcal arthritis 
dermatitis syndrome is the main type of DGI and is the main cause of bacterial arthritis 
in sexually active teenagers and young adults. Gonococcal osteomyelitis is a rare com-
plication of gonococcal arthritis. Rapid response to therapy is usually noted but is slow 
if purulent synovial effusions are noted. Osteomyelitis requires a much longer treatment 
regimen. 
Treatment of DGI is usually with ceftriazone (1 gram IM or IV) every 24 hours until 
improvement develops, often given for at least a week or more; alternative antibiotics 
are cefotaxime (1 gram IV every 8 hours) or ceftizoxime (1 gram IV every 8 hours). After 
24 to 48 hours of clinical improvement, therapy can be switched to oral cefixime. Pa-
tients should also be treated for presumed C. trachomatis. See the 2010 STD guidelines 
from the CDC (1 ). 
18.9 HSV 
Infection HSV, type I, causes 10-20 percent of genital herpes, while type II causes the 
majority. Type I can lead to herpes labialis, keratitis, eczema herpeticum, and gingi-
vostomatitis (1 0,11 ). There is an increase in HSV-1 anogenital herpes in young 
women and MSM. More than 50 million individuals in the United States (more 
than 500 million worldwide) have genital HSV infection, and the highest incidence 
is in the adolescent and young adult age group. Only one-quarter of those with 
HSV-2 infection have known genital disease, and most cases are acquired from some-
one without known disease because of viral shedding in both asymptomatic and 
symptomatic persons. Latency and reactivation phenomena are classic with HSV 
infections. 
A number of clinical presentations for HSV-2 are noted, including a first clinical epi-
sode that is primary (with no prior HSV history and being sero-negative for testing), a 
nonprimary first clinical episode (with a first recognized clinical episode and sero-
positive for HSV-1 and HSV-2), recurrent clinical episodes (with recognized, repeat 
clinical episodes and sero-positive for HSV-2), and asymptomatic presentation (with 
no recognized clinical episode but sero-positive for HSV-2). 
Classic clinical HSV-2 in the female presents as a cervicitis or vulvovaginitis that has 
a mucopurulent discharge in association with vulvar ulcerations. There can be orophar-
yngitis, urethritis, and proctitis. Typically, there is itching or hyperesthesia followed by 
a number of small-group vesicles with erythematous bases that change or rupture into 
small shallow tender ulcers. These painful lesions can persist for 3 to 14 days before 
disappearing without scarring. The lesions may arise on various locations of the genitals 
(vulva, cervix, penis, periurethral but can spread to the vaginal, scrotum, urethra, anus, 
perianal areas, rectum, thighs, or buttocks. One or more deeper ulcers can be seen with 
primary disease in association with fever, headache, general malaise, anorexia, and 
inguinal lymphadenopathy. Uncommon complications to herpes genital infection 
include erythema multiforme, meningitis, ascending myelitis, radiculomyelitis (with 
acute urinary retention), and hepatic failure. 
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The following box lists supportive laboratory data; cell culture and PCR (NAAT) are 
the recommended HSV tests for symptomatic patients. The Giemsa or Wright stain can 
reveal balloon cells with intranuclear bodies or multinuclear giant cells with electron 
microscopy. A Papanicolaou (Pap) smear can reveal multinuclear giant cells; these 
can also be seen in varicella and herpes zoster. Those with genital, anal, or perianal 
ulcers should be screened for syphilis and herpes; consider H. ducreyi if this is locally 
prevalent. Laboratory testing for syphilis includes dark field examination (at least one 
daily for 3 days) and syphilis serology (vida infra). Management of herpes labi alis 
includes oral or topical antiviral agents, sunscreen, zinc oxide cream, and topical anes-
thetic agents. ll> Tab. 18.7 lists recommended antiviral treatment for HSV genital infec-
tion. Topical antiviral therapy should be avoided with HSV genital infections. 
Famciclovir and val acyclovir have greater oral bioavailability and may offer the conve-
nience of less frequent dosing compared to oral acyclovir. Antiviral treatment does not 
eliminate latent virus. Research is ongoing with recombinant glycoprotein vaccines 
being developed. 
Tab. 18.7: Antivi ra l management fo r HSV genital infection (1). 
1. First ep isode (continue over 10 days if lesions not fully resolved) 
a. Acyclovir, 400 mg, o rally, three times a day for 7- 10 days, or 
b. Acyclovir, 200 mg, o rall y, five times a day fo r 7-10 days, or 
c. Va lacyclovir, 1 gram, orally, two times a day for 7-10 days, or 
d. Famciclovi r, 250 mg, orally, three times a day for 7-1 0 days 
2. Recurrent episodes (shortens du ration of lesions) 
a . Acyclovir: 
800 mg, ora ll y, two times a day, for 5 days 
400 mg, orall y, three times a day for 5 days 
800 mg, orally, three times a day for 2 days 
Or 
b. Valacyclovir 
1 gram, orall y, once a day for 5 days 
500 mg, orally, twice a day for 3 days 
Or 
c. Famciclovi r 
125 mg, orally, two times a day for 5 days or 
1000 mg, ora ll y, twice over one day or 
500 mg orally; then 250 mg oral ly twi ce a day fo r 2 days 
3. Suppressive management (red uces frequency of recurrences) 
a. Acyclovir, 400 mg, orall y, two times a day, or 
b. Famciclovir, 250 mg, ora ll y, two times a day, or 
c. Va lacyclovir, 1 gram or 500 mg, orally, once a day (valacyclovir at 500 mg 
may be less effective for those :2:1 0 episodes/year) 
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18.1 0 T. vagina/is 
There are 5 million STD cases in the United States due to trichomoniasis; half are 
asymptomatic in femal es, and it is found in 5 percent of males attending an STD clinic 
(15,16,17,18,19). Preva lence in 18 to 26 year olds is 2.8 percent in females and 
1.7 percent in males. Three trichomonas species are identified in humans: T. bucca/is 
in the mouth, T. hominis in the gastrointestinal tract, and T. vagina/is in the genital 
tract. T. vagina/is is a unicellular, flagellated protozoan that commonly causes a va-
ginitis and cervicitis with secondary vulvitis and urethritis. T. vagina/is is spread sex-
ually including through close genital contact. It has been noted to survive for a few 
hours in wet towels. The incubation period is 4-30 days, after which genital tract 
infection occurs involving the vagina, cervix, bladder, urethra, Skene's (periurethral) 
and Bartholin's glands. 
The vagina is erythematous and contains a profuse, greenish (or gray or yellow-
green), frothy ("bubbly") or malodorous discharge. It is intensely pruritic with a pH 
of 5.0-5.5 or higher. A mucopurulent or turbid vaginal discharge may be noted in 
10 to 15 percent, but this can also be seen with herpes simplex infection, chlamydia 
infection, and gonorrhea. "Strawberry marks" (vaginocervical ecchymosis, 2% of infec-
tions) and swollen vaginal papillae are classic for trichomoniasis. There may be vaginal 
bleeding with genital trauma from coitus or even touching the genital area with a cotton 
swab. Dysuria is frequent and severe cases may present with low abdominal pain as 
well as excoriation of the vulva or inner thighs. Adolescents may be more prone to 
severe symptomatology than adults. Postpartum trichomoniasis has been noted with 
fever, leukorrhea, and endometritis. A prolonged carrier state is possible and may be 
associated with menses - induced, acute exacerbations, as well as chronic pelvic 
congestion, dysmenorrhea, and menorrhagia. 
The differential diagnosis includes vulvavaginitis due to N. gonorrhoeaeCandida 
a/bicans, or BV. The presence of the leukorrhea or cervical infection is not enough 
for diagnosis. For example, what appears as an "inflamed" cervix may be a benign 
cervical erosion in which the endocervical columnar epithelium spreads out of the 
cervica l canal, forming a border around the external os. 
The saline drop (sensitivity of 60%- 70%), Pap smear, and/or culture (most sensitive) 
can aid with the diagnosis, A saline preparation reveals numerous pear-shaped moti le 
microbes which are unicellular flagell ated organisms twice the size of a white blood 
cell. These microbes may not be seen in chronic carriers if urine is the sample study 
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or if the patient used a chemical douche prior to the exam. The lubricant used on the 
speculum can also hinder this test result. These organisms can also be noted in urine 
samples or on Pap smears. However, the Pap smear can result in false negative- as 
well as false positive results. Cultures are possible in some laboratories; these are help-
ful in suspicious cases with multiple negative saline preparations. FDA-cleared tests 
include OSOM Trichomonas Rapid Test (color immunochromatographic [dipstick] 
technology) and Affirm VP Ill; the latter is a nucleic acid probe test for T. vaginalisC. 
albicans, and C. vagina/is. 
Treatment is with nitroimidazoles as metronidazole and tinidazole. Metronidazole 
can be given as a single 2-gram dose, or tinidazole is given at 2 grams orally in one 
dose; an alternative regimen for metronidazole is a 7-day oral course (500 mg twice 
a day). Those who drink alcohol need to avoid this substance during treatment and 
for up to 24 hours after taking metronidazole and 72 hours after taking tinidazole. 
Treatment with metronidazole gel should be avoided. 
Follow-up is not necessary if the clinical symptoms rapidly resolve while the uncom-
mon resistant infection (not reinfection) can be treated with the 7-day course (500 mg 
BID) of metronidazole; if the infection is still not resolved, 2 grams (single dose) of me-
tronidazole is given once a day for 3- 5 days (1 ). Vaginal infection is associated with 
adverse pregnancy outcomes and pregnant patients with T. vagina/is vaginitis can be 
treated with the single 2-gram dose regimen of metronidazole. Those with an immedi-
ate-type allergy to metronidazole can be treated with desensitization. Resistance to 
nitroimidazoles remains limited. 
Metronidazole does have numerous side effects including monilial vaginitis, confu-
sion, ataxia, nausea and anorexia, headache, dizziness, transient neutropenia, metallic 
taste, dermatitis, dry mucosal surfaces, urine discoloration, and peripheral neuropathy. 
Flushing and nausea with emesis occurs when metronidazole is combined with alcohol 
due to a disulfiram effect. The single 2-gram dose may reduce many of the side effects 
for the disulfiram effect. Tinidazole side effects are similar to metronidazole but also 
include postmarketing reports of severe dermatological reactions including erythema 
multiforme and Stevens-Johnson syndrome. As noted, avoid alcohol for 72 hours 
after taking tinidazole. 
18.11 BV 
In this sexually associated (or enhanced) infection, there is an increased growth of 
anaerobic bacteria in the vagina, including C. vaginalisMobiluncus species, Bacter-
oides species, Prevotella species, Ureaplasma, and others; Mycoplasmas hominis is 
also noted, while lactobacilli are reduced. BV induces a vaginitis characterized by a 
nonitchy, gray-white, frothy, malodorous vaginal discharge with a pH usually less 
than 4.5; specific cervical or bladder infection is not found. BV can be noted in as 
many as 50 percent of sexual assault victims evaluated within 72 hours of the assault 
(23). Transient C. vagina/is bacteremia has also been seen, usually associated with 
delivery or abortion. In sexually active individuals the presence of BV also increases 
the risks for gonococcal, trichomonal, and chlamydia! genital infection in addition to 
HIV and HSV-2 . The frequency of coital behavior and numbers of sexual partners 
may be factors for BV acquisition in some females. 
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Cl inically, the vaginal discharge, vaginal pH, Whiff test, and wet mount for clue ce lls 
are used for the diagnosis of BV. Gram stains of vaginal fluid, typically only obtained 
in research studies, reveal decreased lactobacilli and increased anaerobic bacteria. 
A saline preparation or Grain stain of the leukorrhea identifies clue cells - epithelial 
cells covered ("studded") with many gram-negative bacilli; a positive sample is when 
20 percent or more of the epithelial cells are covered with bacteria. The sensitivity 
of the wet mount test is 70-90 percent (vs. 75%-80% for the low pH) and specificity 
is 95-100 percent (vs. 60%-70% for the low pH test). A less proven test is producing 
an amine-like odor when a small amount of this discharge is mixed with 10 percent 
potass ium hydroxide (I<OH) solution (Whiff test). There is also a DNA probe to detect 
high concentrations of G. vagina/is; the Affirm VP Ill test, as noted earlier, can detect 
C. vagina/is . 
.,.. Tab. 18.8 lists the 2010 CDC recommended treatment options for symptomatic BV. 
Follow-up of nonpregnant patients with BV who resolve with recommended treatment 
is usually not necessary. There are no recommendations to treat the male partner of 
the female with BV, and it remains debated whether or not to treat asymptomatic BV 
in pregnant women without a previous history of preterm delivery, since it does not 
prevent preterm labor and delivery. 
18.12 HPV 
HPV is a double-stranded DNA virus that accounts for 20 million or more STDs in the 
United States (6,7,8,9). HPV subtypes are identified with an immunoblot typing system; 
more than 100 types are now recognized, including these often associated with clinical 
symptomatology with approximately 40 that infect the genitals and at least 14 that are 
oncogenic. Types 6 and 11 lead to genital condylomas, and type 16 is the most 
Tab. 18.8: Management of BV (1 ). 
Preferred (nonpregnant, nonlactating) 
• Metronidazole (500 mg BID orally for 7 days) or 
• Clindamyc in cream (2%) (one full applicator [5 grams] intravaginally before bedtime for 7 days) 
or 
• Metronidazole gel (0.75%) (one full applicator [5 grams] intravaginally, once a day for 5 days) 
Alternative (nonpregnant, nonlactating) 
• Tinidazole (2 grams orally once dail y for 2 days) or 
• Tinidazole (1 gram orally once daily for 5 days) or 
• Clindamycin (300 mg orally twi ce a day for 7 days) or 
• Clindamycin ovules (1 00 mg intravaginally once at bedtime for 3 days) 
Preferred (pregnant) 
• Metronidazole (500 mg orally, twice a day, for 7 days) or 
• Metronidazole (250 mg orally, three times a day, for 7 days) or 
• Clindamycin (300 mg ora lly BID for 7 days) 
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common cause of anogenital cancer. Other oncogenic types include 18,31 ;33,35,39, 
45,51,52,58,59,68,73, and 82. There is an incubation period of a few weeks to several 
months; it infects basal epithelial cells. It is sexually transmitted and is often associated 
with other infections (C. albicans) and STDs (as trichomoniasis and gonococcal 
cervicitis). 
HPV is noted in 3-8 percent of unselected young female patients; 25-50 percent of 
patients seen in an STD clinic were noted to have HPV using co lposcopy . As many as 
70 percent of these particular patient's sex partners displayed warts or had them before. 
Biologic risk factors for acquiring HPV include the presence of cervical ectopy, micro-
trauma, and immature immune response capacity. Most HPV infections are acquired 
early in the sexual life of the patient and youth may be more vulnerable to this infection 
than adults, from a biological viewpoint. Viral protein transcription leads to various 
HPV manifestations: warts, dysplasia, and cancer. The HPV wart lesion may involve 
any part of the genitals (including the vagina, urethra, bladder, or anal canal), and 
the infection can be very extensive. They seem to worsen in individuals with vaginal 
discharge, poor hygiene, heavy perspiration, and pregnancy. Lesions resistant to treat-
ment are reported in some individuals with insulin-dependent diabetes mellitus and 
with immunosuppressive disorders. 
Most HPV infections in humans are asymptomatic and are only detected by colpo-
scopy or Pap smear testing. Thus, the prevention of HPV infections with the HPV vac-
cines is recommended for females and males from ages 9 to 26 years of age "in 
contrast" to treating the warts or cancer that develop after the infection. The bivalent 
vaccine (Cervarix) offers protection against HPV types 16 and 18, while the quadriva-
lent vaccine (Gardasil) offers protection against HPV types 6,11,16, and 18. The 
quadrivalent vaccine provides protection against the two most common HPV strains 
that cause genital warts. The vaccine is a three-dose series, and common side effects 
include fever, injection site reactions, arthralgias, and fatigue. Syncope sometimes as-
sociated with tonic-clonic movements or other seizure-like activity has been re-
ported, and observation of the patient for 15 minutes after administration is 
recommended. 
The Bethesda system LSIL (low-grade squamous intraepithelial lesions) corresponds 
to the World Health Organization CIN (cervical intraepithelial neoplasia) I classifica-
tion versus HSIL (high-grade squamous intraepithelial lesion), which reflects CIN II 
and Ill. HPV is necessary for the development, maintenance, and progression of CIN; 
HPV is linked to cervical and vulvar neoplasia as well as anal cancer, penile cancer, 
and oropharyngeal cancer. Though the timing of starting Pap smears is controversial, 
the American College of Obstetricians and Gynecologists recommends initial Pap 
smear screening at age 21 regardless of the sexual history. 
The differential diagnosis of HPV warts includes molluscum contagiosum, condy-
loma lata (syphilis), skin tags (peri-anal), urethral prolapsed, and pearly penile papules. 
The presence of squamous papillomas in moist mucocutaneous areas of the external 
genitalia and perianal regions is usually sufficient for its diagnosis. Biopsy is confirma-
tory and mandatory if lesions are resistant to podophyllin therapy. Voiding cystoure-
thrography will demonstrate if intraurethral spread has occurred. Colposcopy is used 
by some clinicians but there are problems with access and cost. Cytology (Pap 
smear) is the most practical diagnostic tool but has low sensitivity and specificity. 
Molecular diagnostic modalities include in situ hybridization, dot-blot (commercially 
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available ViraPapNira Type), Southern blot, and PCR. The PCR is the most sensitive test 
for HPV. Hybrid Capture is FDA approved to evaluate 14 high-risk or cancer-associated 
HPV types . 
..,.. Tab. 18.9 lists the therapy options for warts. Therapy of concomitant STDs and 
using 10-25 percent tincture of podophyllin (podophyllum resin in tincture of benzoin) 
on the lesions may be helpful, especially if the areas are less than 2 em in diameter. 
White petrolatum jelly may be then added and this mixture of podophyllin, and 
white petrolatum jelly is thoroughly washed off in 2-4 hours. There are other techni-
ques for using podophyllin, but these all stress that normal tissue must be protected 
from the caustic podophyllin that induces pain. Weekly applications may be necessary 
and seems to be most effective with moist, fleshy, sessile genital warts. The role of 
more frequent application is under study, and the goal of treatment is to remove the 
symptomatic wart. Regression is noted in 79 percent within 2 years, and there is no 
evidence that treatment of overt warts affects the development of cervical cancer. Per-
sistent infections are associated with smoking, other STDs, multiple partners, and 
immunosuppression states. 
Podophyllin is not used for cervical warts or for pregnant patients. If there is not 
regression after four weekly trial s, other methods are used. Unfortunately, there is no 
treatment proven to eradicate this virus and no specific regimen to always remove 
the warts and prevent recurrences. In addition, no one treatment suites all patients 
and therapy should be individualized. The use of topical chemotherapeutic agents 
(as 80%-90% trichloroacetic acid [01< for pregnancy and mucosa] or 5-fluorouracil) 
has been used as alternatives to topi ca l podophyllin treatment. Podofilox (0.5%) is 
available for home use; others include lmiquimod 5 percent cream and Sinecatechins 
15 percent ointment. None of the at-home treatments have been adequately assessed in 
pregnancy. 
Tab. 18.9: Treatment options for external genital warts (1) . 
A. Topical application 
• Patient applied: 
Podofilox 0.5% solution or gel 
lmiquimod 5% cream 
Sinecatech ins 15% ointment 
• Provider administered: 
Cryotherapy with liquid nitrogen or cryoprobe 
Podophyllin resin 10%-25% (in compound tincture of benzoin) 
Trichloraceti c acid or bi chloroacetic ac id 80%-90% 
B. Other 
• ·Surgical remova l of warts 
• lntrales ional interferon injection 
• Laser surgery 
• Topi ca l cidofovir 
348 I 18 Sexually transmitted diseases (STDs) 
Methods that have been recommended as alternatives to podophyllin therapy 
include curettage, electrocauterization, loop electrosurgical excision procedure, 
alpha interferon, surgical excision, and cryotherapy (with liquid nitrogen or solid car-
bon dioxide). Immunotherapy with an autogenous vaccine (prepared from excised 
warts) has been attempted but is without proven success. Laser treatment has also 
been used with success. Careful follow-up of these patients is important, due to the 
link of this virus to cervical cancer and other cancers. 
18.13 Vulvovaginitis 
Puberty exerts a profound estrogen effect on the female genital tract that produces 
a thicker, longer vagina with an adult effect on the vaginal cell count: approxi-
mately 60 percent superficial cells, 31 percent intermediate, and 9 percent paraba-
sal. The pH is in the acidic range (5.0 to 5.5) due to lactic acid production partially 
from the presence of lactobacilli (see the following box, "Normal Flora of the 
Vagina after Puberty"). One result of this thickened, acidic vaginal milieu is in-
creased protection against infection . Vulvovaginitis tends to be due to specific 
causes (~Tab. 18.1 0), many of which are covered earlier in this chapter. The pres-
ence of certain identified pathogens (i.e. N. gonorrhoeaeT. vagina/is C. albicans C. 
vagina/is) does not always mean asymptomatic infection exists; sometimes a trig-
gering mechanism (often not known) must occur before overt symptomatology 
occurs. 
Tab. 18.10: Causes of vulvovaginitis. 
1. Leukorrhea and/or vaginitis 
a. Physiologic leukorrhea 
b. C. albicans vaginitis 
c. BV 
d. T. vagina/is vaginitis 
2. Cervicitis due to 
a. C. trachomatis 
b. Ne. gonorrhoeae 
c. HSV 
3. Miscellaneous 
a. Allergic vulvovaginitis 
b. Foreign body vaginitis 
c. Vulvar ulcerations (herpes, syphilis, chancroid, lymphogranuloma venereum granuloma 
inguinale, amebiasis, Behcet's syndrome, others) 
d. Vulvitis (scabies, molluscum contagiosum, pediculosis, warts [HPV], tinea, psoriasis, 
furunculosis, pruritus vulvae, others) 
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18.14 Physiological leukorrhea 
Physiologic leukorrhea refers to a normal increase in vaginal discharge (leukorrhea) 
due to puberty-stimulated increase in estrogen production; it ca n also be noted in 
the first few days or weeks after birth in the female newborn due to ematernal estro-
gen. In early puberty the vaginal discharge is from mucus secretion of the cervical 
co lumnar epithelium, vaginal wall fluid transudation, and multiple gland stimulation 
(i.e. Bartholin's, sebaceous, and sweat). Classically it initiates several weeks or 
months prior to menarche and is variable in amount usually until regular menstruation 
is established. 
The leukorrhea is typically clear, sticky, and nonirritating and may increase during 
pregnancy or even during sexual arousal. A saline preparation of the vaginal fluid re-
veals normal vaginal cytology without leukocytes or pathogenic bacteria. Cultures of 
the vaginal fluid are not necessary but, if obtained, are negative. The young adolescent 
female may be concerned that it is due to genital injury or an STD. Nylon undergar-
ments absorb the fluid poorly in contrast to the excellent absorptive powers of cotton 
undergarments. Good perineal hygiene is recommended with normal baths, and med-
ication is to be avoided; inadvertent use of medication can lead to such sequelae as 
dermatitis medicamentosa. 
18.15 C. albicans 
Vulvovaginal candidiasis (VVC) is a common cause of vulvovaginitis not classified as 
an STD and due to C. a/bicans in 80-90 percent, Torulopsis glabrata in 10- 15 percent, 
and C. parapsilosis in 1-2 percent. .,.. Tab. 18.11 I ists various precipitating factors in the 
development of recurrent or chronic VVC. VVC typically presents with vagina-vulvar 
erythema, intense pruritis, and a whitish, cheese- like vaginal discharge with a pH of 
3.8 to 5.0 (typically <4.5). Itchiness with erythema and decreased leucorrhea may 
occur if the infection is precipitated by antibiotics; more leukorrhea occurs if VVC 
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Tab. 18.11: Precipitating factors for chronic or recurrent VVC. 
1. Removal of normal vaginal flora with Candida overgrowth due to broad-spectrum antibiotics 
2. Reduction of host defense mechanism 
a. Chronic illness 
b. Steroids 
c. Aging 
d. Severe iron deficiency anemia 
e. Immune disorders 
3. Chronic Candida exposure 
a. Infected sex partner 
b. Contaminated soaps 
c. Intestinal reservoir 
4. Increase in heat or moisture 
a. Obesity 
b. Tight nylon undergarments 
5. Lower the pH 
a. Pregnancy 
b. Oral contraceptives 
c. Diabetes mellitus 
develops during pregnancy. Increase in the discharge may occur before and after 
menstruation but decrease during menstruation. 
Other symptoms that may occur include urinary frequency, dysuria, and dyspareu-
nia. There may also be fissuring, lichenification, and secondary bacterial infection 
over the perineal areas or legs (including the thighs). Skene's glands and endocervical 
glands may also be infected. The presence of thickened, bronzed, or dull red skin over 
the labia or groin suggests chronic infection. Dermatophytids (Monilids) can develop as 
very pruritic, but sterile lesions at the sides of the fingers and hands. Laboratory testing 
reveals a vaginal secretion with a pH under 5.0, while a 10 percent KOH preparation 
shows hyphae (mycelia), pseudo-hyphae (nondetached buds), yeast (oval cells), and 
possibly white blood cells; the exam in negative for clue cells and trichomonads. 
Culture can also be accomplished. 
The only FDA-approved oral medication is fluconazole that is given as 1 SO mg tablet 
(~Tab. 18.12). A number of azole agents are available as topical agents, as noted in 
~Tab. 18.12, that are oil-based and thus may weaken latex condoms and diaphragms. 
Topical azoles are considered more effective than nystatin and are recommended for 
use during pregnancy; short courses (1-3 days) are as effective as longer courses. C. al-
bicans can be found in as many as 20 percent of females without VVC symptoms, and 
antifungal treatment is usually not indicated in this situation. Treatment of sexual part-
ners of females with symptomatic VVC is not recommended unless she has recurrent 
or chronic disease. A minority of male sex partners of femal es with VVC may develop 
balanitis that usually resolves with topica l antifungal agents; other potential causes of 
balanitis include HSV and primary syphilis. 
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Tab. 18.12: Management of VVC. 
1. Oral agent: fluconazole* (150 mg oral tab) in a single dose 
2. Clotrimazole: 
• cream (1%) (5 grams) intravaginally for 7-14 days or 
• cream (2%) (5 grams) intravaginally for 3 days 
3. Miconazole nitrate: 
• vaginal cream (2%) once daily (5 grams) for 7 days 
• vaginal cream (4%) once daily (5 grams) for 3 days 
• 200 mg vaginal suppository, one suppository for 3 days 
• 100 mg vaginal suppository, one suppository for 7 days 
• 1,200 mg vaginal suppository - use once 
4. 2% butaconazole nitrate (Femstat) cream - 5 grams given intravaginally for 3 days 
5. Others include tioconazole and terconazole* and as topical agents 
*Prescription only. 
Females with recurrent VVC due to C. albicans may be managed with a short course 
of fluconizole (1 00 to 200 mg every 3 days for 3 doses) or 1 to 2 weeks of topical 
agents; longer "maintenance" antifungal treatment may be considered (1 ). Most have 
uncomplicated VVC. Complicated VVC is not well understood and involves those fe-
males with recurrent VVC (four or more episodes per year - found in <5%), severe 
VVC, non-albicans candidiasis, or those with uncontrolled diabetes mellitus or immu-
nosuppression states. Females with non-albicans VVC can be treated with nonflucona-
zole azole drugs (oral or topical) for 7 to 14 days. Numerous drug interactions exist with 
oral azole agents due to cytochrome P450 enzyme metabolism and inhibition. A pa-
tient's medication regimen should be reviewed for drug interactions before initiating 
an oral azole medication . If further infection occurs, use boric acid (600 mg) in a 
gelatin capsule intravaginally, once a day, for 14 days (1 ). 
18.16 Miscellaneous STDs 
Many other STDs are noted in youth. HIV is discussed in section 18.17.1. Reiter 
syndrome is considered in the rheumatology chapter (chapter 13). Group A strepto-
cocci can cause a vaginitis in prepubertal females after transmission by sexual contact 
or autoinoculation from the pharynx; management is with 10 days of penicillin . 
..,.. Tab. 18.13 outlines treatment for pediculosis pubis (due to Pthirus pubis) and scabies 
(due to 5. scabiei). Increasing resistance with permethrin and pyrethrins may require use 
of malathione if treatment failure occurs for pediculosis pubis. Due to the neurological 
toxicities associated with lindane, permethrin and ivermectin are considered first line 
treatments for scabies. Lindane and ivermectin should not be used during pregnancy. 
Pinworms (Enterobius vermicularis) may cause rectal and vaginal irritation as well as 
pruritus. The worms may be found in the perianal area at night or identified with the 
cellophane tape test. Treat with pyrantel pamoate (nonprescription: 11 mg/kg with 
maximum of 1 gram orally; repeat in 2 weeks) or with prescription medications: 
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Tab. 18.13: Treatment options for pediculosis pubis and scabies (1 ). 
A. Pediculosis pubis 
• Permethrin (1% cream rinse- apply to affected areas; wash off in 10 minutes) or 
• Pyrethrins (with piperonyl butoxide- apply to affected areas; wash off in 10 minutes) 
Alternative: 
• Malathione (0.5% lotion applied for 8 to 12 hours; wash off) or 
• lvermectin (250 meg/kg orally; repeat in 2 weeks) 
B. Scabies 
• Permethrin* (5% cream -apply from neck down; wash off in 8 to 14 hours) or 
• lvermectin* (200 meg/kg orally; repeat in 2 weeks) 
Alternative: 
• Lindane* (1%): 1 oz. (30 gram) of cream applied in a thin layer to all areas from the neck 
down; wash off thoroughly after 8 hours; do not apply directly after bathing. 
*Prescription only. 
mebendazole (1 00 mg tablet once and may need to repeat in 2 weeks) or albendazole 
(400 mg tablet and repeat in 2 weeks; unlabeled indication). All family members in 
close contact with the patient should also be treated. See the dermatology chapter 
(chapter 1) for consideration of other conditions that may be associated with sexual 
behavior, such as tinea cruris, contact dermatitis, and molluscum contagiosum. 
LGV is an STD due to infection with C. trachomatis (serotypes L 1, L2, and L3) with an 
incubation period of 3 to 30 days; it causes inguinal lymphadenopathy (buboes) that is 
painful as well as genital ulcers and severe ulcerative proctitis (proctocolitis). The pri-
mary lesion may be a small red erosion (often missed) with fever, malaise, myalgias, 
and arthralgias. Unilateral lymph nodes above and below the inguinal ligament are 
called the "groove" sign. Untreated LGV can lead to bowel obstruction, bowel perfo-
ration, rectal strictures, and even death. Molecu lar testing is available to establish a 
diagnosis of LGV while treatment involves doxycycline (100 mg orally, twice daily, 
for 21 days); an alternative plan is erythromycin base (500 mg orally QID for 
21 days). Erythromycin should be used during pregnancy and in lactating females. 
Chancroid (due to H. ducreyi) has an incubation period of 3 to 14 days and presents 
with a small, painful, erythematous papule that classically erodes into a ragged ulcer 
with undetermined edges; there is usually painful , often unil ateral, inguinal lympha-
denopathy that may be supporative. Laboratory data may include culture (often diffi-
cult to obtain) and PCR testing. Management is with ceftriaxone (250 mg IM), 
ciprofloxacin (500 mg BID for 3 days) or azithromycin (1 gram orally); an alternative 
plan is erythromycin base (500 mg TID for 7 days). Fluoroquinolones should be 
avoided during pregnancy and in lactating fema les. 
Granuloma ingui nale (donovanosis) is due to infection with /(. granulomatis (for-
merly called Calymmatobacterium granulomatis) that has in incubation period of 2 to 
10 weeks and presents with an erythematous nodule or papule that is usually nonpain-
ful but then ulcerates to form fri able, beefy-red granulation tissue; tissue biopsy can 
note Donovoan bodies. Inguinal lymphadenopathy is not usually noted but perilym-
phatic granulomas ("pseudobubos") may mimic enlarged lymph nodes. It is treated 
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with doxycycline (1 00 mg orally, twice daily, for at least 3 weeks) or 160 mg of tri-
methoprim with 800 mg of sulfamethoxazole - one tablet orally, twice daily, for 
3 weeks. Alternative treatments include ciprofloxac in (750 mg orally, twice a day, 
for 3 weeks), erythromycin base (500 mg, orally, four times a day for 3 weeks), or azi-
thromycin (1 gram orally, per week, for 3 weeks). In pregnancy, erythromycin is pre-
ferred and inclusion cif an intravenous aminoglycoside should be cons idered. 
Treatment should continue until all lesions have completely healed and relapses can 
occur despite appropriate treatment. 
Syphilis is an STD of antiquity due to T. pallidum with an incubation period of 9 to 
90 days (average of 3 weeks) (24,25). This pathogenic spirochete gains access via mu-
cosal abrasions during sexual activity with the induction of a local immune response 
and secondary hematogenous spread. Primary syphilis presents with the classic chan-
cre that is a well-defined, painless, erythematous ulcer with a firm (rubbery) base; 
there is usually inguinal lymphadenopathy that can be bilateral or unilateral, and 
typically nontender as well as nonsuppurative. 
Diagnosis is with darkfield microscopy to identify the treponemes and serology (non-
treponema! tests: rapid plasma reagin [RPR], Venereal Disease Research Laboratory 
[VORL]). The sensitivity of RPR or VORL is higher in secondary syphilis versus primary 
or latent syphilis; also, RPR and VORL are associated with false positive results and false 
negative results (prozone reaction). Direct fluorescent antibody testing (DFA-TP) of 
smears can also be used if available. Treponema! tests can be used: fluorescent trepo-
nema! antibody absorption (FTA-ABS) and microhemagglutination assay (MHA-TP) that 
remain positive for a lifetime in most (despite treatment). Screen those with a history of 
exposure to syphilis with an RPR or VORL and if positive, do a treponema! test (i.e. 
MHA-TP or FTA-ABS). 
The chancre lasts 2 to 6 weeks and will resolve even without treatment. Secondary 
syphilis appears 6 weeks to 6 months after disappearance of the chancre and can pres-
ent with a wide variety of constitutional symptomatology in its role as the "Great Imi-
tator" : malaise, fever, generalized lymphadenopathy, hepatospenomegaly, rhinitis, sore 
throat, alopecia ("moth-eaten", patchy), polymorphic rash (with or without involve-
ment of the palms and soles), headache, arthralgias, anogential condylomata lata, 
and many others. 
The rash of syphilis may begin as a red, macu lar eruption first on the extremities and 
trunk; lesions may become elevated with a copper- red hue and involve the palms as 
well as soles. Plaque-like lesions may be seen that mimic psoriasis while the appear-
ance of rings can mimic tinea corporis. Condyloma lata appear as skin-colored or 
gray, macerated papules in the perianal or genital area; there can also be mucous 
patches that present as oval, gray erosions on the genital areas or in the oral cavity. Sec-
ondary syphilis can last 2 or more weeks and also resolve without treatment. Later 
stages can occur that are rarely seen in adolescents, including early latent (within 
1 year of infection), late latent (can persist for many years without symptoms), latent 
syphilis of unknown duration, and tertiary (neurologic, cardiac, gummatous les ions). 
Primary, secondary, and early latent stages of syphilis are treated with Benzathine 
Penicillin G (2.4 million units IM) in one dose; late latent, latent syphilis of unknown 
duration, and tertiary syphilis (not neurosyphili s) are treated with Benzathine Penicillin 
G (2.4 million units IM) weekly for 3 weeks. Neurosyphilis should be treated with intra-
venous penicillin G (18-24 million units per day) for 10-14 days. A patient with 
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syphilis who is allergic to penicillin is desensitized and treated with penicillin. Alterna-
tive treatment in nonpregnant individuals is tetracycline (500 mg, orally, four times a 
day) or doxycycline (100 mg, orally, twice a day) for 14 days. An acute febrile reaction 
called the Jarisch-Herxheimer reaction can occur within 24 hours of initiating treat-
ment; this is typically seen in patients with early syphilis and can be managed with anti-
pyretics. See the CDC STD guidelines (201 0) for management of syphilis including 
neurosyphilis, tertiary syphilis, latent syphili s, and congenital syphilis (1). 
18.17 Homosexuality and STDs in adolescents 
Homosexual behavior may occur during adolescence and eventually, 4 to 6 percent of 
adults will identify themselves as gay, les ian, or bisexual. Young adolescents may only 
find homosexual contact at public places where problems with sexually transmitted dis-
eases (including HIV infection) often exist. Lesbian teens may have sex with males as 
part of their adolescent sexual experimentation and some are at increased risk of 
HIV infection as well as other STDs because of coitus with infected males; pregnancy 
risks also occur in this situation if unprotected sex occurs. 
About 25 percent of those with HIV/acquired immunodeficiency syndrome (AIDS) in 
the United States contracted their infection by the age of 21 years. For those in their 
twenties with HIV, many, if not most of them, were infected while they were still teen-
agers or in their early twenties (see section 18.17 .1 ). Even if the adolescent engages in 
same-sex behavior for economic reasons and not because of being homosexual, risks 
for STDs remain. Advice regarding testing for STDs includes explaining possible risk 
factors, treatment options, and discussion regarding confidentiality as well as informing 
the adolescent's parent, if possible. Advice regarding options for self protection in-
cludes safe sex awareness and practice, including sexual abstinence and use of latex 
condoms. In addition, the adolescent can be taught techniques to handle peer pressure 
regarding sexual behavior. 
The gastrointestinal tract can be involved with acquisition of STD agents in rectal 
(receptive) sexual activity. Proctitis (rectal inflammation) is noted with anorectal 
pain, rectal discharge, and tenesmus due toN. gonorrhoeaeT. pallidum, HSV, C. tra-
chomatitis (including LGV serovars), and others. In proctocolitis, there is abdominal 
cramping, diarrhea, and symptoms of rectal inflammation due to various agents 
(.,..Tab. 18.14). In enteritis due to various opportunistic agents (.,..Tab. 18.15), there is 
mainly abdominal cramping and diarrhea; Giardia Iamblia is the most common 
cause in this situation . 
Treatment depends on the causative agent(s). In proctitis suspected to be due toN. go-
norrhoeae treatment is with ceftriazone (250 mg IM) and doxycycline (1 00 mg orally, 
twice a day for 7 days) to cover C. trachomatis. Consider herpes and LGV serovars as caus-
ative of rectal ulcers and treat accordingly; use 3 weeks of doxycycline (1 00 mg orally, 
twice a day) for LGV treatment. See the 2010 CDC STD management guidelines (1 ). 
18.17.1 HIV/AIDS 
Overall, 1 million individuals are estimated to be infected with the human immunode-
ficiency virus-1 (HIV-1) in the United States with at least one-third seen in those 15 to 
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Tab. 18.14: STDs in homosexual/bisexual adolescents. 
Urethritis 
• N. gonorrhoeae 
• C. trachomatis 
• M. genitalium 
• U. urealyticum 
T. vagina/is 
HSV 
Adenoviruses 
Pharyngitis 
• N. gonorrhoeae 
• HSV 
• T. pallidum 
• Others 
AIDS (persons with HIV infection may acquire various other opportunistic infections not listed) 
Genital warts (infection with HPV) 
Ectoparasites (Pthirus pubisSarcoptes scabiei) 
Hepatitis 
• Hepatitis A, B, C, D, and/or E virus 
• Cytomegalovirus 
• Epstein-Barr virus 
Ulcerative lesions 
• Syphilis (T. pallidum) 
• HSV 
• Chancroid (H. ducreyi) 
• LGV (C. trachomatis) 
• Granuloma inguinale (K. granufomatis) 
Enteriti s/proctocol iti s 
• C. Iamblia 
• Salmonella enteritidis 
• Entamoeba histolytica 
• Cryptosporidium species 
• Campylobacter species 
• Shigella species 
• C. trachomatis 
• LGV serovars 
Reprinted with permission from: Greydanus DE, Patel DR, Pratt HD, Calles JL jr, eds. Behavioral 
pediatrics, 2nd edn. New York: iUniverse, 2006:456. 
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Tab. 18.15: Antiretroviral (ART) medications (partial list). 
A. Nonnucleoside reverse transcriptase inhibitors (NNRTis) 
• Efavirenz 
• Nevirapine 
• Delaviridine 
• Etravirine 
• Rilpivirine 
B. Protease inhibitors 
• Atazanavir 
• Darunavir 
• Fosamprenavir 
• Lopinavir 
• Saquinavir 
• Tipranavir 
• Ritonavir 
• lndinavir 
• Nelfinavir 
C. Nucleoside reverse transcriptase inhibitors (NRTJs) 
• Abacavir 
• Emtricitabine 
• Lamivudine 
• Tenofovir 
• Zidovudine 
• Didanosine 
• Stavudine 
D. lntegrase strand transfer inhibitor 
• Raltegravir 
E. Cellular chemokine receptor 5 antagonist 
• Maraviroc 
29 years of age; approximately half of new infections are found in those under age 25. 
HIV-2 is prevalent in West Africa. Minority populations suffer disproportionately higher 
numbers of HIV infection. This virus is transmitted via sexual activity, needle sharing, 
and also in breast milk. 
The main mode of transmission in males having HIV is MSM often with injection 
drug use, though it can affect any gender or age group that is exposed. The introduction 
of zidovudine (formerly called azidothymidine [abbreviated AZT]) has greatly reduced 
mother-to-child transmission at this time. Primary risk categories in adolescent females 
and young women for HIV infection include heterosexual behavior complicated by 
injection drug use. Another group of HIV-infected adolescents is those who were 
infected prenatally and are now in the adolescent age group. 
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Testing involves use of the HIV EINWestern blot and should be done according to 
local state guidelines for HIV testing (1). Generally antibody testing initiates with a 
screening test such as an EIA, and then reactive screening tests are confirmed with a 
test such as the Western blot test or immunofluorescence assay. A continued positive 
test indicates the individual is infected with this virus (HIV) and can infect others. 
Seroconversion usually occurs within 3 months after infection but may take up to 
12 months; a negative testing scheme does not rule out a recent infection. Plasma 
HIV RNA testing (plasma viral load test) can be obtained in situations when a patient 
has symptomatology consistent with acute HIV infection but HIV antibody testing is 
negative or inconclusive. The RNA viral load test measures the amount of free HIV 
virus (non cell bound) in the infected person. Follow-up testing (i.e. Western blot) 
can be done in two to four months to confirm HIV infection if the plasma HIV plasma 
testing indicates HIV infection. 
Though most newly diagnosed patients are asymptomatic, some can develop acute 
retroviral syndrome 2 to 6 weeks after HIV infection before HIV testing becomes 
positive. A variety of symptoms are noted including fever, malaise, skin rash, and lym-
phadenopathy. These youth may benefit from early use of anti-HIV medications (anti-
tretroviral drugs) and should be referred to local experts in HIV management. The 
patient with AIDS has the development of an opportunistic infection or AIDS-defining 
ailment in one infected with HIV or a drop in the patient's CD4 lymphocyte count 
to 200 cells/mm3 or less. Those with HIV/AIDS develop a wide, protean variety of 
potential symptomatology and disorders including generalized lymphadenopathy, 
hepatomegaly, splenomegaly, failure to thrive, oral thrush, recurrent diarrhea, hepatitis, 
parotitis, cardiomyopathy, nephropathy, central nervous system disease, lymphoid 
interstitial pneumonia, recurrent invasive bacterial infections, opportunistic infections, 
and malignant neoplasms. 
ART management is recommended for all those with HIV and AIDS, and referral to 
local experts in an HIV/AIDS center is recommended to ensure the best treatment for 
this very complex situation with ever-changing protocols and recommendations. De-
tailed discussion of management is beyond the scope of this chapter and this book. 
ART medications are generally divided into five different groups (~Tab. 18.15), and 
ways to improve adherence to this regimen are listed in ~Tab. 18.16. Detailed instruc-
tions are provided at http://www.aidsinfo.nih.gov, and it is vital to provide in a program 
with well-trained health care professionals who adhere to updated protocols. The med-
ications are complex with many side effects and drug interactions. Complicating the 
overall treatment is the many potential opportunistic infections that may be seen that 
can be difficult to treat. The patient should make a commitment to a lifetime of treat-
ment that will result in the best possible life span and quality of life, especially as new 
discoveries are made with research now and in the future. 
Classification is based predominantly on the CD4 count and different protocols may 
be used based on if the patient has or has not received ART (ART-na"ive vs. ART-
experienced); another important factor is the plasma HIV RNA load. Genotype testing 
is recommended to optimize regimen selection due to the potential for drug resistance. 
Early ART treatment helps to protect the patient's sex partner from becoming infected 
with HIV; correct condom use with all coitus is also important in this preventive 
scheme. Combination of ARTs is more effective than monotherapy, and protocols gen-
erally use three ART drugs from two different classes, such as including two NRTis 
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along with a protease inhibitor or NNRTI (~Tab. 18.15). Individualizing therapy 
is essential, and attempts are made to simplify the treatment protocol to maximize 
compliance with the treatment protocols (~Tab. 18.16). 
Tab. 18.16: Strategies to improve adherence to ART therapy strategies. 
Use a multidisciplinary team approach 
Provide an accessible, trusting health 
care team 
Establish a trusting relationship with the 
patient 
Establish readiness to start ART 
Identify potential barriers to adherence 
prior to starting ART 
Provide resources for the patient 
Involve the patient in ART regimen 
selection 
Assess adherence at every clinic visit 
Identify the type of nonadherence 
Identify reasons for nonadherence; assess 
and simplify regimen, if possible 
Nurses, social workers, pharmacists, and medication 
managers 
Psychosocial issues 
Active substance abuse or at high risk of relapse 
Low literacy level 
Busy daily schedule and/or travel away from home 
Lack of disclosure of HIV diagnosis 
Skepticism about ART 
Lack of prescription drug coverage 
Referrals for mental health and/or substance abuse 
treatment 
Resources to obtain prescription drug coverage 
Pillboxes 
For each option, revi ew potential side effects, dosing 
frequency, pill burden, storage requirements, food 
requirements, and consequences of nonadherence 
Use a simple checklist the patient can complete in 
the waiting room 
Have other members of the health care team also 
assess adherence 
Ask the patient open-ended questions (e.g. In the last 
3 days, please tell me how you took your 
medicines.) 
Failure to fill the prescription(s) 
Failure to take the right dose(s) at the right time(s) 
Nonadherence to food requirements 
Adverse effects from medications 
Complexity of regimen (pill burden, dosing 
frequency, etc.) 
Diff iculty swallowing large pills 
Forgetfu I ness 
Failure to understand dosing instructions 
• Inadequate understanding of drug resistance and 
its relationship to adherence 
Pill fatigue 
Other potential barriers (see I ist above) 
From http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.PDF. Accessed May 12, 
2011. Table 12. 
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18.18 Conclusions 
High rates of unprotected sexual behavior in adolescents result in millions of cases of 
STDs in the world. This chapter reviews factors inducing high STD rates, specific STDs, 
and their management based on 2010 CDC STD guidelines. Clinicians should screen 
all their sexually active adolescent patients for STDs and provide preventive education 
as well as treatment measures. 
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